裁判，公判 of COVID-19 血 plasma finds no 利益 in 厳しく ill 患者s
By Kate Kelland
LONDON, Jan 11 (Reuters) - An international 裁判，公判 実験（する）ing convalescent 血 plasma on COVID-19 患者s with 穏健な and 厳しい illness has 停止（させる）d enrolment of 厳しく ill COVID-19 患者s 要求するing 集中的な care after it 設立する no 利益, 裁判，公判 捜査官／調査官s said on Monday.
The 決定／判定勝ち（する） by the REMAP-CAP 裁判，公判 leaders （機の）カム after an 初期の 分析 of more than 900 厳しく ill 裁判，公判 関係者s in 集中的な care showed that 治療 with the 製品 - an antibody-rich plasma taken from people who have 回復するd from the pandemic 病気 - did not 改善する 結果s.
"There was no 証拠 of 害（を与える） associated with the 行政 of convalescent plasma" (and) the 裁判，公判 is continuing to 新採用する 入院させるd COVID-19 患者s who are moderately ill but not in 集中的な care, scientists 主要な the 裁判，公判 said in a 声明.
"It is biologically plausible that 患者s who are not producing antibodies at the time of convalescent plasma therapy and those 患者s with 超過 ウイルス may 利益 more than others. Our 付加 分析するs will 調査する this," said Manu Shankar-Hari, a clinician and professor of 批判的な care 薬／医学 at Britain's Guy´s and St Thomas´ hospital, who is co-主要な the 裁判，公判.
He 追加するd that the 初期の 分析 did not 査定する／（税金などを）課す plasma's 影響s in 入院させるd 患者s with いっそう少なく 厳しい 病気. This "remains a very important question" and would continue to be 調査するd in the 現在進行中の 裁判，公判, he said.
The underlying hypothesis for using convalescent plasma as a 可能性のある 治療 for COVID-19 患者s is that the antibodies it 含む／封じ込めるs could 中立にする／無効にする the ウイルス, stopping it from replicating and 停止（させる）ing tissue 損失.
But this 初期の 分析 主要な to the REMAP-CAP pause in enrolment of 批判的に ill 患者s showed there was a very low probability - 2.2% - that it 減ずるd death 率s or 減少（する）d the number of days 患者s needed 集中的な care.
"Why convalesc ent plasma does not seem to 改善する 結果 in 厳しく ill COVID-19 患者s 認める to the ICU is not yet known. However, it may be because the 肺 損失 is too 前進するd for convalescent plasma to make a difference," said Alexis Turgeon, a 批判的な care doctor and professor at Universit? Laval in Canada, who is also working on the 裁判，公判.
REMAP-CAP is an international 臨床の 裁判，公判 調査するing 可能性のある 治療s for COVID-19. It has already 新採用するd 4,100 COVID-19 患者s at more than 290 臨床の 場所／位置s across Europe, the Americas, Asia, Africa and Australasia.
Separate findings from REMAP-CAP showed last week that 扱う／治療するing 批判的に ill COVID-19 患者s with Roche's Actemra or Sanofi's Kevzara arthritis 麻薬s 意味ありげに 改善するd 生き残り 率s and 減ずるd the 量 of time 患者s need 集中的な care.
The 裁判，公判 is also looking at 可能性のある 影響s of a 範囲 of other 存在するing therapies, 含むing anticoagulation 薬／医学s, antiplatelet スパイ／執行官s, 抗生物質s, statins and ビタミン C. (報告（する）／憶測ing by Kate Kelland; Editing by Nick Macfie)
